A single-arm trial of advanced HER2-positive gastric cancer patients treated with chemotherapy and two targeted agents (trastuzumab and bevacizumab) reported longer progression-free survival than the ToGA trial, which treated patients with chemotherapy and trastuzumab only.44 Here, ERBB2 is linked to gastric cancer.